Evaluation of RP3 Monotherapy and RP3 Plus Nivolumab in Patients with Advanced Solid Tumors

The primary objective of this study is to evaluate the efficacy and safety of **RP3** as a monotherapy and in combination with **Nivolumab** in patients with **advanced solid tumors**. This is clinically relevant as it aims to determine the potential therapeutic benefits and safety profile of RP3, both alone and in conjunction with an established immunotherapy agent, Nivolumab, which could lead to improved treatment options for patients with these challenging malignancies.

The clinical trial involves a total of **46 participants** diagnosed with **advanced solid tumors**. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. Participants were selected without targeting any vulnerable populations. The trial does not specify any particular lifestyle considerations such as diet, physical activity, or habits. The sponsor has not provided detailed information regarding the main objective of the trial or specific inclusion criteria. The general health status of the participants is not explicitly mentioned, but it is implied that they are affected by advanced stages of solid tumors.

The clinical trial is designed to evaluate the efficacy and safety of **RP3** monotherapy and its combination with **Nivolumab** in patients diagnosed with **advanced solid tumors**. This study is structured as a Phase 1 trial, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The trial is set to commence recruitment on July 20, 2022, and is projected to conclude by November 1, 2027, encompassing a comprehensive duration to adequately assess the therapeutic outcomes.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, where eligibility criteria are assessed. This initial visit is crucial for determining participant suitability based on predefined inclusion and exclusion criteria. Following successful enrollment, participants will attend regular follow-up visits, which are scheduled to monitor treatment response, manage any adverse events, and ensure adherence to the study protocol. These visits are integral to maintaining the integrity of the trial and collecting consistent data over time. The study will culminate in an end-of-study visit, where final assessments are conducted to evaluate the overall impact of the treatment regimen.

The expected length of participant involvement in the trial is contingent upon individual response to treatment and the occurrence of any adverse events. Participants may be subject to early termination from the study if they experience significant adverse reactions, fail to comply with the study protocol, or withdraw consent. Such conditions are in place to prioritize participant safety and uphold ethical standards throughout the trial. The structured design and rigorous procedures of this clinical trial aim to contribute valuable insights into the treatment of advanced solid tumors, potentially informing future therapeutic strategies.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date for the trial is July 20, 2022, with an anticipated end date of November 1, 2027. Although specific efficacy parameters or endpoints are not detailed, Phase 1 trials typically involve the collection of preliminary data on the treatment's effects. The methods for measuring, collecting, and analyzing efficacy data are not specified, but such trials often utilize a combination of laboratory tests, validated scales, and patient-reported outcomes to gather relevant information. The trial's duration and phase suggest a focus on initial safety assessments, with potential secondary observations on efficacy to inform subsequent trial phases.